Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NS-050/NCNP-03 in Boys With Duchenne Muscular Dystrophy (DMD)
NCT06053814Phase 2Active, not recruiting
- Sponsor
- NS Pharma, Inc.
- Start
- Sep 2024
- Primary completion
- Mar 2028
- Modality
- Modified DNA Oligonucleotides, Single-strand DNA, Antisense Oligonucleotides (ASOs)
- Countries
- 5
01
Overview
A Phase 2 trial of NS-050 in Duchenne muscular dystrophy (DMD), sponsored by NS Pharma, Inc.. Started Sep 2024; status: active, not recruiting.
02
Drugs
NS-050
03
Conditions
Duchenne muscular dystrophy (DMD)
Beyond the preview
Go deeper on NCT06053814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06053814.